PRAX: Praxis Precision Medicines - A High-Risk, High-Reward Bet on a Volatile Biotech

Key Takeaway:

• Extreme volatility - the stock has swung from $26 to $206 in the past 12 months.
• No revenue, no profit, but a deep pipeline - the company is essentially a bet on its clinical-stage drugs.
• Catalyst-heavy - upcoming trial readouts and regulatory decisions could send the stock soaring or crashing.

---

1. The Stock in One Sentence

Praxis Precision Medicines (PRAX) is a clinical-stage biotech company with a volatile stock price, no revenue, and a pipeline of CNS drugs that could either be worth billions or nothing at all.

---

2. The Numbers That Matter

Metric	Value
Stock Price	$181.99
Market Cap	$4.58 billion
52-week range	$26.70 - $206.71
Cash & Cash Equivalents	$1.2 billion
Debt	$0

---

3. The Pipeline - The Real Story Behind the Stock

Drug	Indication	Phase	Notes
Ulixacaltamide	Essential Tremor	Phase 3	Fast-tracked by FDA; pivotal data due Q1 2026
Vormidiprant	Schizophrenia	Phase 2	Orphan drug status; pivotal data due Q2 2026
PRAX-020	Autism Spectrum Disorder	Phase 2	Early data suggests potential blockbuster

---

4. The Risks

• Binary Outcomes: The stock is a binary bet on trial readouts.
• Dilution Risk: The company has enough cash for 2-3 years, but biotechs often raise capital when stocks surge.
• Regulatory Risk: The FDA could reject any of these drugs for any reason.

---

5. The Bottom Line

• High risk, high reward.
• Not for the faint-hearted.
• A potential 10-bagger or a total loss.

---

Bottom Line: Praxis is a high-risk, high-reward play on a biotech with a volatile stock price and a pipeline of drugs that could be worth billions or nothing at all.